Claims
- 1. A compound of the structural formula: ##STR30## or N-oxide, or an opthalmologically acceptable salt thereof wherein: ##STR31## is a pyrido, dihydropyrido or tetrahydropyrido group with the N at the 4-, 5-, 6- or 7-position; and
- R is
- (1) C.sub.1-5 alkyl, either straight chain, branched chain or cyclic and either unsubstituted or substituted with hydroxy, amino, C.sub.1-5 alkylamino or di(C.sub.1-5 alkyl)amino, the alkyl groups of which can be joined together to form a 5-7 membered heterocycle,
- (2) Hydrogen
- (3) --OR.sup.1, wherein R.sup.1 is hydrogen, C.sub.1-5 alkyl, amino-C.sub.1-3 alkyl, C.sub.1-3 alkylamino-C.sub.1-3 alkyl, di(C.sub.1-3 alkyl) amino-C.sub.1-3 alkyl, hydroxy-C.sub.1-3 alkyl, or C.sub.2-4 alkanoyl,
- (4) ##STR32## wherein m is 0-3 and n is 0, 1 or 2, (5) --N(R.sup.1).sub.2 wherein the R.sup.1 groups can be the same or different, or joined together to form a 5-7 membered heterocycle
- (6) halo selected from the group consisting of chloro, bromo and fluoro,
- (7) --NO.sub.2, or
- (8) oxo-; and if ##STR33## represents a dihydro- or tetrahydropyrido- the N can be substituted with R.sup.1 or --CONH.sub.2.
- 2. The compound of claim 1 wherein ##STR34##
- 3. The compound of claim 2 wherein R is hydrogen, hydroxy, hydroxy-C.sub.1-5 alkyl, C.sub.1-5 alkylamino-C.sub.1-5 alkyl, or di(c.sub.1-5 alkyl)amino-C.sub.1-5 alkyl.
- 4. The compound of claim 3, which is:
- 2-sulfamoyl-4-methoxyfuro[3,2-c]pyridine;
- 2-Sulfamoylfuro[2,3-c]pyridine;
- 2-Sulfamoylfuro[3,2-c]pyridine;
- 2-Sulfamoyl-4-chloro-furo[3,2-c]pyridine;
- 2-Sulfamoyl-4-(2-hydroxyethylamino)furo[3,2-c]pyridine; or
- 2-Sulfamoyl-4-[2-(dimethylamino) ethylamino]furo[3,2-c]pyridine; or an opthalmologically acceptable salt thereof.
- 5. An opthalmological formulation for treating elevated intraocular pressure comprising an ophthalmologically acceptable carrier and an effective intraocular pressure lowering amount of a compound of claim 1 or an ophthalmologically acceptable salt thereof.
- 6. The formulation of claim 5, wherein ##STR35##
- 7. The formulation of claim 6, wherein R is hydrogen, hydroxy, hydroxy-C.sub.1-5 alkyl, C.sub.1-5 alkylamino-C.sub.1-5 alkyl or di(C.sub.1-5 alkyl)amino-C.sub.1-5 alkyl.
- 8. The formulation of claim 7, wherein the compound is:
- 2-Sulfamoyl-4-methoxyfuro[3,2-c]pyridine;
- 2-Sulfamoylfuro[2,3-c]pyridine;
- 2-Sulfamoylfuro[3,2-c]pyridine;
- 2-Sulfamoyl-4-chloro-furo[3,2-c]pyridine;
- 2-Sulfamoyl-4-(2-hydroxylethylamino)furo[3,2-c]pyridine; or
- 2-Sulfamoyl-4-[2-(dimethylamino)ethylamino]furo[3,2-c]pyridine; or an ophthalmologically acceptable salt thereof.
- 9. A method of treating elevated intraocular pressure which comprises the administration to a patient in need of such treatment of an effective intraocular pressure lowering amount of the compound of claim 1.
- 10. The method of claim 9, wherein ##STR36##
- 11. The method of claim 10, wherein R is hydrogen, hydroxy, hydroxy-C.sub.1-5 alkyl, C.sub.1-5 alkylamino-C.sub.1-5 alkyl, or di(C.sub.1-5 alkyl)amino-C.sub.1-5 -alkyl.
- 12. The method of claim 11, wherein the compound is:
- 2-Sulfamoyl-4-methoxyfuro[3,2-c]pyridine
- 2-Sulfamoylfuro[2,3-c]pyridine;
- 2-Sulfamoylfuro[3,2-c]pyridine;
- 2-Sulfamoyl-4-chloro-furo[3,2-c]pyridine;
- 2-Sulfamoyl-4-(2-hydroxyethylamino)furo[3,2-c]pyridine; or
- 2-Sulfamoyl-4-[2-(dimethylamino) ethylamino]furo[3,2-c]pyridine; or an ophthalmologically acceptable salt thereof.
Parent Case Info
This is a continuation-in-part of copending application, Ser. No. 129,202, filed Dec. 7, 1987, now abandoned, which in turn is a continuation of copending application, Ser. No. 946,228, filed Dec. 24, 1986, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4544667 |
Shephard et al. |
Oct 1985 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
129478 |
Dec 1984 |
EPX |
2081712 |
Jun 1981 |
GBX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
946228 |
Dec 1986 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
129202 |
Dec 1987 |
|